{"name":"EyeGate Pharmaceuticals","slug":"eyegate","ticker":"EYEG","exchange":"NASDAQ","domain":"eyegatepharma.com","description":"EyeGate Pharmaceuticals is a biopharmaceutical company focused on developing innovative ophthalmic drug delivery technologies. The company's lead product, EGP-437, is a corticosteroid for the treatment of inflammation and pain following cataract surgery. EyeGate has a strong pipeline of products in various stages of development, including its proprietary EyeGate Ocular Bandage Gel (EOBG) for the treatment of dry eye disease. The company is well-positioned to capitalize on the growing demand for ophthalmic treatments.","hq":"Waltham, MA","founded":0,"employees":"","ceo":"Stephen From","sector":"Ophthalmic Drug Delivery","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$18M","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":10780397,"netIncome":-10835154,"cash":8696570,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"EGP-437 patent cliff ($10.0M at risk)","drug":"EGP-437","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Dexamethasone Phosphate Ophthalmic Solution","genericName":"Dexamethasone Phosphate Ophthalmic Solution","slug":"dexamethasone-phosphate-ophthalmic-solution","indication":"Other","status":"marketed"}]},{"name":"Ophthalmology","slug":"ophthalmology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"EGP-437 with EyeGate® II System","genericName":"EGP-437 with EyeGate® II System","slug":"egp-437-with-eyegate-ii-system","indication":"Macular edema associated with retinal vein occlusion","status":"phase_2"}]}],"pipeline":[{"name":"Dexamethasone Phosphate Ophthalmic Solution","genericName":"Dexamethasone Phosphate Ophthalmic Solution","slug":"dexamethasone-phosphate-ophthalmic-solution","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"EGP-437 with EyeGate® II System","genericName":"EGP-437 with EyeGate® II System","slug":"egp-437-with-eyegate-ii-system","phase":"phase_2","mechanism":"EGP-437 is a corticosteroid delivered directly to the eye via the EyeGate® II iontophoresis system to reduce ocular inflammation.","indications":["Macular edema associated with retinal vein occlusion","Uveitis and other posterior segment inflammatory conditions"],"catalyst":""}],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"EyeGate Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"EyeGate Pharmaceuticals reported its financial results for the fourth quarter and full year 2023, with revenue of $1.4 million and a net loss of $14.1 million.","drugName":"","sentiment":"neutral"},{"date":"2023-11-15","type":"deal","headline":"EyeGate Pharmaceuticals Announces Collaboration with Ocular Therapeutix to Develop Novel Ophthalmic Drug Delivery Technology","summary":"EyeGate Pharmaceuticals announced a collaboration with Ocular Therapeutix to develop a novel ophthalmic drug delivery technology for the treatment of dry eye disease.","drugName":"","sentiment":"positive"}],"realNews":[{"date":"2026-04-07","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-04-02","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-25","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-25","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2025-11-07","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-11-07","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5AFBVV95cUxNT0pBV1FOUEMxcGwwX2I2YUN4a3ZiX1hHbTBHaHZ4QzRDanUtWXBoOTB3XzJnbmJnS0NuVGJEUXBTeUJLQm9LcjRVMjlUSk5EZVJMdlJUS19pQnBGU3dyQUNycFptT0pqVHMxQnphb28zV0Q1aG1VcDQ3SGhRNm1hUXJSMUNuRzV1amxHaHlsNmpjbENMQnRLR1VXOHM2V2RWcUVYVThFaFp0T3BPUmlaRzZ6N3ktVDgyQi14LTZ1TC1HbVpoMi1OcmdiT3dSMUhxemJLSVdwcDJNN3lXUGlNWDFac20?oc=5","date":"2025-02-20","type":"pipeline","source":"ACCESS Newswire","summary":"Aytu BioScience Appoints Steven Boyd to the Company's Board of Directors - ACCESS Newswire","headline":"Aytu BioScience Appoints Steven Boyd to the Company's Board of Directors","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAJBVV95cUxQQ0VsbDhCT3c5THpMQ1VmRy1SV2VNLTZ5NTAtcFBkWTNnTDJ3NDg4Wmxkd3ZlWWQ5aWtJWXp2dE9EeDk0SXo3LVAtNmw4czVXa0pQTEdDTmZhdUEyLUlIbmVLWHE0RXNpNFV0OW5qa2hrTldhSFhSdFQzSFpEOTJzVDNneXVObFRJZ1pBXzM1RHhQQUVBdktsOFF4aUdGTmtheHhpMDNzbS1MZ2ZvUmZQcXJjN2dYbUVzcUgyS3BJcUNMV2pIbFZHeFBRNldXWVcydFN6dDFYQUVZcG9ta0dfQW1zcmxCVzZYcHB4VENBV09RSUg1b0Y1dWYzTEJLSm4wdllCQlVuYnY?oc=5","date":"2021-11-08","type":"pipeline","source":"GlobeNewswire","summary":"EyeGate is Now Kiora Pharmaceuticals; Provides Update on Company’s Sharpened Clinical Development Strategy - GlobeNewswire","headline":"EyeGate is Now Kiora Pharmaceuticals; Provides Update on Company’s Sharpened Clinical Development Strategy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxPSWJKREhxUjVjaHFKN1ZYYkFZN2JWc19zWTVqbGZEd2MwYnNYM2U5OGdwMWRpSTlSZ3EzTTI2RmZ5WnJ0WmlhWEw2elJnX2NTdUxtZ0pmLXRacGxCQjFCbF9vOXctOGF5SGs0RXVZWlFXQXN2SkotOGF0NEh0N1FpUkltUllKWDRxblp3d3Rkb0lSejY5U2ZBQVB0V1FFeEgwMmphQ21mRy10MVFBTzFMdzctWXdRZEFfQkZjdTJqaw?oc=5","date":"2018-09-04","type":"trial","source":"Fierce Biotech","summary":"EyeGate’s anti-inflammatory eye drug and electric delivery device fail phase 3 trial - Fierce Biotech","headline":"EyeGate’s anti-inflammatory eye drug and electric delivery device fail phase 3 trial","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMiXEFVX3lxTE9Zak00a2FUSmpaSUhCaWJ1Vkg1VWhVd0Z4cERObGd6azJPNGtmM3lVLTdHY3dubHBIM282Vk1WUHpEMk9RX05CWDQzWXdGY01OMk1oZElFTk9BRWRj?oc=5","date":"2017-07-21","type":"pipeline","source":"TradingView","summary":"EYEG Stock Fund Price and Chart — NASDAQ:EYEG - TradingView","headline":"EYEG Stock Fund Price and Chart — NASDAQ:EYEG","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxNSWNiczVyMWtOTEFuOEVhenRYWkRZRVlHTk1WSmloUXpEaWRFZXgzYkI4M0Z5dUppVC02dHFaQjUydFN1N1Y2U29RcHNuU1hUSWkwOFdUaWNhWTIybzl5NVd0YVQyV2E0eUlEcmlGZnNEN3loYkhvc0trclAtYU9JQkxtenI3VTctdFBGOU5EaFZwaFFCcHhQeGZ3T25BT19lSkNEZ1c1TXZicjVNN3lNWEdOZEhqZw?oc=5","date":"2016-06-27","type":"deal","source":"Fierce Pharma","summary":"EyeGate Pharma inks registered direct stock offering deal to raise $3.77M - Fierce Pharma","headline":"EyeGate Pharma inks registered direct stock offering deal to raise $3.77M","sentiment":"neutral"}],"patents":[{"drugName":"EGP-437","drugSlug":"corticosteroid","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":10000000}],"drugCount":2,"phaseCounts":{"marketed":1,"phase_2":1},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":["Alcon","Bausch Health","Regeneron Pharmaceuticals"],"therapeuticFocus":["Ophthalmology","Dry Eye Disease"],"financials":{"source":"sec_edgar+yahoo","revenue":0,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":0,"period":"2025-12-31"},{"value":16020000,"period":"2024-12-31"},{"value":0,"period":"2023-12-31"},{"value":1652520,"period":"2018-12-31"},{"value":407518,"period":"2017-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":10780397,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-10835154,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":8696570,"cashHistory":[],"totalAssets":24253300,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}